Use of proton pump inhibitors is associated with fractures in young adults: a population-based study

被引:81
|
作者
Freedberg, D. E. [1 ]
Haynes, K. [2 ]
Denburg, M. R. [3 ]
Zemel, B. S. [4 ]
Leonard, M. B. [5 ,6 ]
Abrams, J. A. [1 ]
Yang, Y. -X. [2 ,7 ]
机构
[1] Columbia Univ, Div Digest & Liver Dis, Med Ctr, New York, NY 10032 USA
[2] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Div Nephrol, Philadelphia, PA 19104 USA
[4] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
[5] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA
[6] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA
[7] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA
关键词
Acid suppression medications; Bone mineral density; Fracture; Histamine-2 receptor antagonists; Osteoporosis; Outcomes research; Pediatrics; Pharmacoepidemiology; Proton pump inhibitors; BONE-MINERAL DENSITY; GASTROESOPHAGEAL-REFLUX DISEASE; NETWORK THIN DATABASE; CALCIUM-ABSORPTION; RISK; CHILDREN; EPIDEMIOLOGY; VALIDATION; ACID; OSTEOPOROSIS;
D O I
10.1007/s00198-015-3168-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Summary Proton pump inhibitors (PPIs) are associated with risk for fracture in osteoporotic adults. In this population-based study, we found a significant association between PPIs and fracture in young adults, with evidence of a dose-response effect. Young adults who use PPIs should be cautioned regarding risk for fracture. Introduction Proton pump inhibitors (PPIs) are associated with fracture in adults with osteoporosis. Because PPI therapy may interfere with bone accrual and attainment of peak bone mineral density, we studied the association between use of PPIs and fracture in children and young adults. Methods We conducted a population-based, case-control study nested within records from general medical practices from 1994 to 2013. Participants were 4-29 years old with a parts per thousand yen1 year of follow-up who lacked chronic conditions associated with use of long-term acid suppression. Cases of fracture were defined as the first incident fracture at any site. Using incidence density sampling, cases were matched with up to five controls by age, sex, medical practice, and start of follow-up. PPI exposure was defined as 180 or more cumulative doses of PPIs. Conditional logistic regression was used to estimate the odds ratio and confidence interval for use of PPIs and fracture. Results We identified 124,799 cases and 605,643 controls. The adjusted odds ratio for the risk of fracture associated with PPI exposure was 1.13 (95 % CI 0.92 to 1.39) among children aged < 18 years old and 1.39 (95 % CI 1.26 to 1.53) among young adults aged 18-29 years old. In young adults but not children, we observed a dose-response effect with increased total exposure to PPIs (p for trend < 0.001). Conclusions PPI use was associated with fracture in young adults, but overall evidence did not support a PPI-fracture relationship in children. Young adults who use PPIs should be cautioned regarding potentially increased risk for fracture, even if they lack traditional fracture risk factors.
引用
收藏
页码:2501 / 2507
页数:7
相关论文
共 50 条
  • [1] Use of proton pump inhibitors is associated with fractures in young adults: a population-based study
    D. E. Freedberg
    K. Haynes
    M. R. Denburg
    B. S. Zemel
    M. B. Leonard
    J. A. Abrams
    Y.-X. Yang
    Osteoporosis International, 2015, 26 : 2501 - 2507
  • [2] Use of proton-pump inhibitors is associated with depression: a population-based study
    Laudisio, Alice
    Incalzi, Raffaele Antonelli
    Gemma, Antonella
    Giovannini, Silvia
    Lo Monaco, Maria Rita
    Vetrano, Davide L.
    Padua, Luca
    Bernabei, Roberto
    Zuccala, Giuseppe
    INTERNATIONAL PSYCHOGERIATRICS, 2018, 30 (01) : 153 - 159
  • [3] Proton pump inhibitor use is associated with hip fracture development: a nationwide population-based cohort study
    Min, Yang Won
    Lee, Yeong Chan
    Kim, Kyunga
    Ryu, Seungho
    Hong, Kyoung Sub
    Jeon, Han Ho
    Kim, Yong Sung
    Park, Jong Heon
    Son, Hee Jung
    Rhee, Poong-Lyul
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (05) : 1084 - 1093
  • [4] Proton-pump inhibitor use and hip fractures in men: a population-based case-control study
    Adams, Annette L.
    Black, Mary Helen
    Zhang, Jian L.
    Shi, Jiaxiao M.
    Jacobsen, Steven J.
    ANNALS OF EPIDEMIOLOGY, 2014, 24 (04) : 286 - 290
  • [5] Association between opioid use disorder and fractures: a population-based study
    Hsu, Wen-Yu
    Lin, Cheng-Li
    Kao, Chia-Hung
    ADDICTION, 2019, 114 (11) : 2008 - 2015
  • [6] Association Between Proton Pump Inhibitors and Asthma: A Population-Based Cohort Study
    Wang, Yao-Tung
    Tsai, Ming-Chang
    Wang, Yu-Hsun
    Wei, James Cheng-Chung
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [7] Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures
    Fournier, Marc R.
    Targownik, Laura E.
    Leslie, William D.
    MATURITAS, 2009, 64 (01) : 9 - 13
  • [8] Proton Pump Inhibitors and Hypomagnesemia in the General Population: A Population-Based Cohort Study
    Kieboom, Brenda C. T.
    Kiefte-de Jong, Jessica C.
    Eijgelsheim, Mark
    Franco, Oscar H.
    Kuipers, Ernst J.
    Hofman, Albert
    Zietse, Robert
    Stricker, Bruno H.
    Hoorn, Ewout J.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (05) : 775 - 782
  • [9] Use of proton pump inhibitors and risk of rosacea: A nationwide population-based study
    Dai, Ying-Xiu
    Tai, Ying-Hsuan
    Chen, Chih-Chiang
    Chang, Yun-Ting
    Chen, Tzeng-Ji
    Chen, Mu-Hong
    JOURNAL OF DERMATOLOGY, 2020, 47 (10) : 1126 - 1130
  • [10] Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
    Pouwels, S.
    Lalmohamed, A.
    Souverein, P.
    Cooper, C.
    Veldt, B. J.
    Leufkens, H. G.
    de Boer, A.
    van Staa, T.
    de Vries, F.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) : 903 - 910